Clinical Research Headquarters
929 North Front Street
PPD is part of Thermo Fisher Scientific. As the world’s leader in serving science, our professionals develop critical solutions—and build rewarding careers. We offer services and products that help customers around the globe in laboratories and clinics, on production lines and out in the field.
We’re a driving force in the research, healthcare, industrial and applied markets, generating more $35 billion in annual revenue. No other company can match our range of customer touch points—technologically, geographically or commercially. We help customers in finding cures for cancer, protecting the environment, bringing medicines to market, making sure our food is safe and moving forward with thousands of important projects that improve millions of lives.
Stock Symbol: TMO
Stock Exchange: NYSE
Find PPD on social media:
Find PPD Careers on social media:
We All Have Our Why | PPD
444 articles about PPD
Enhancing its ability to conduct complex, procedurally intensive Phase I and Phase Ib early development clinical research in neurology, PPD has added a 52-bed CRU in Orlando, Florida.
Recognized for commitment to decreasing patient burden in clinical trials
PPD Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering
The initial public offering is expected to commence after the SEC completes its review process, subject to market and other conditions.
Providing new patient treatment options, accelerating development of life-changing medicines
This recognition affirms the excellence and dedication of PPD® Laboratories professionals in helping advance clients’ antibody-drug conjugate (ADC) research to develop new anticancer therapies.
Enhancing immunochemistry, biomarker and chromatography services for biopharma clients
Evidera and CSS Collaborate to Develop Joint Real-world and Patient-centered Research Capabilities in Japan
Evidera, a business unit of Pharmaceutical Product Development, LLC (PPD), has entered into an exclusive collaboration agreement with Clinical Study Support, Inc. (CSS), a subsidiary of Shin Nippon Biomedical Laboratories Ltd. (SNBL), extending both organizations’ capabilities to deliver more robust consulting and analytical capabilities and creating a more complete geographic customer solution for clinical, real-world and patient-centered research.
First-patient-in milestone achieved in only two weeks with Cancer Treatment Centers of America
Strong site relationships key to quality execution, on-time delivery for biopharmaceutical customers
The recognition follows PPD’s inclusion earlier this year on Forbes’ list of America’s Best Employers for Diversity.
Anchored by Raleigh, Durham and the Research Triangle Park region, BioSpace’s Bio NC Hotbed is one of the faster-growing areas for biopharma in the U.S.
Pharmaceutical Product Development, LLC (PPD), a leading global contract research organization dedicated to improving health, has been named to Forbes magazine’s 2019 list of America’s Best Employers for Diversity
Jing Tu has been selected as the 2018 winner of the Bioanalysis Rising Star Award, selected from among 30 nominees across the globe.
Award recognizing PPD’s commitment to innovation for advancing and accelerating the drug development process.
Gotham Therapeutics launched in New York with a $54 million Series A financing. The focus is on a subgroup of RNA metabolism called epitranscriptomics. This involves the biochemical modifications of RNA within a cell, which have an impact on gene expression.
Expanding Global Oncology Testing for Clinical Trials
Substantially Increases Ability to Support Large Molecule Development
Provides Personalized Support for Patients and Enhances Retention for Clients
Pharmaceutical Product Development, LLC (PPD) today announced it has been honored for employee learning and development programs that help the global contract research organization deliver service excellence to its pharmaceutical and biotechnology clients.
PPD today announced that Maria Teresa Hilado, chief financial officer of Allergan, has been named to PPD’s board of directors.